About The Study: In this study, monthly, 140 mg erenumab injections safely and effectively achieved medication overuse headaches remission in patients with nonopioid chronic migraine and medication overuse headaches within 6 months.
Quote from corresponding author Stewart J. Tepper, MD:
"Those patients with medication overuse headache (MOH) have higher disability and a significant unmet clinical need. Erenumab proved effective versus placebo in significantly higher rates of MOH remission and marked reduction in days in which acute migraine treatment was taken in a randomized controlled trial, with these benefits sustained through a one- year open label treatment period.
"The change for clinical care will be that practitioners can start patients with MOH on erenumab and expect a likelihood of MOH remission for most without other interventions, such as planned wean, inpatient detoxification, or behavioral therapies. This will simplify and improve care of MOH patients."
Contact information for Stewart J. Tepper, MD: email [email protected].
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaneurol.2024.3043)
